Production of complex virus-like particles in insect cells

Fabiana Fernandes, Ana P. Teixeira, Nuno Carinhas, Manuel J.T. Carrondo, P.M. Alves

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A cost-effective manufacturing process yielding sufficient quantity and quality of a multigenic product is generally not an easy task to accomplish due to product complexity. Despite the success of the BEVS in producing VLP-based vaccines for both veterinary and human use, its performance regarding the expression of complex VLPs has room for improvement. The yields of correctly assembled VLPs and associated levels of baculovirus contamination are still not satisfactory according to commercial requirements. Significant efforts to address these issues continue to be directed towards ameliorating molecular design for the construction of more efficient and reliable expression systems. Nonreplicative rBVs represent one advance that aims at debottlenecking the problem of contamination of the VLP bulk with viral material. Stable protein expression through engineered insect cell lines constitutes another alternative since it does not rely on viral infection for protein production, thus minimizing downstream challenges. Still, VLP production will benefit from improvements in downstream processes that could improve recovery yields without compromising quality. Further work should also be conducted towards tuning the expression levels of each protein subunit to improve the assembly efficiency of complex VLPs and also the consistency of the final product composition. Ultimately, advances in the fields of systems biology and genetic engineering will complement each other towards the development of faster, robust and simpler production processes based on effective biological hosts and vectors. In the end, all will contribute to the sustainability of the insect cell technology and reinforce its credibility as a platform for the production of complex VLP vaccines.

Original languageEnglish
Title of host publicationVirus-like Particles in Vaccine Development
PublisherFUTURE MEDICINE LTD
Pages120-134
Number of pages15
ISBN (Electronic)9781780844176
ISBN (Print)9781780844190
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Virion
Insects
Vaccines
Genetic Engineering
Systems Biology
Baculoviridae
Protein Subunits
Viral Proteins
Virus Diseases
Technology
Costs and Cost Analysis
Cell Line
Proteins

Cite this

Fernandes, F., Teixeira, A. P., Carinhas, N., Carrondo, M. J. T., & Alves, P. M. (2014). Production of complex virus-like particles in insect cells. In Virus-like Particles in Vaccine Development (pp. 120-134). FUTURE MEDICINE LTD. https://doi.org/10.2217/FMEB2013.13.67
Fernandes, Fabiana ; Teixeira, Ana P. ; Carinhas, Nuno ; Carrondo, Manuel J.T. ; Alves, P.M. / Production of complex virus-like particles in insect cells. Virus-like Particles in Vaccine Development. FUTURE MEDICINE LTD, 2014. pp. 120-134
@inbook{a08bf3ea8e4447209299f58408b861c4,
title = "Production of complex virus-like particles in insect cells",
abstract = "A cost-effective manufacturing process yielding sufficient quantity and quality of a multigenic product is generally not an easy task to accomplish due to product complexity. Despite the success of the BEVS in producing VLP-based vaccines for both veterinary and human use, its performance regarding the expression of complex VLPs has room for improvement. The yields of correctly assembled VLPs and associated levels of baculovirus contamination are still not satisfactory according to commercial requirements. Significant efforts to address these issues continue to be directed towards ameliorating molecular design for the construction of more efficient and reliable expression systems. Nonreplicative rBVs represent one advance that aims at debottlenecking the problem of contamination of the VLP bulk with viral material. Stable protein expression through engineered insect cell lines constitutes another alternative since it does not rely on viral infection for protein production, thus minimizing downstream challenges. Still, VLP production will benefit from improvements in downstream processes that could improve recovery yields without compromising quality. Further work should also be conducted towards tuning the expression levels of each protein subunit to improve the assembly efficiency of complex VLPs and also the consistency of the final product composition. Ultimately, advances in the fields of systems biology and genetic engineering will complement each other towards the development of faster, robust and simpler production processes based on effective biological hosts and vectors. In the end, all will contribute to the sustainability of the insect cell technology and reinforce its credibility as a platform for the production of complex VLP vaccines.",
author = "Fabiana Fernandes and Teixeira, {Ana P.} and Nuno Carinhas and Carrondo, {Manuel J.T.} and P.M. Alves",
year = "2014",
month = "1",
day = "1",
doi = "10.2217/FMEB2013.13.67",
language = "English",
isbn = "9781780844190",
pages = "120--134",
booktitle = "Virus-like Particles in Vaccine Development",
publisher = "FUTURE MEDICINE LTD",

}

Fernandes, F, Teixeira, AP, Carinhas, N, Carrondo, MJT & Alves, PM 2014, Production of complex virus-like particles in insect cells. in Virus-like Particles in Vaccine Development. FUTURE MEDICINE LTD, pp. 120-134. https://doi.org/10.2217/FMEB2013.13.67

Production of complex virus-like particles in insect cells. / Fernandes, Fabiana; Teixeira, Ana P.; Carinhas, Nuno; Carrondo, Manuel J.T.; Alves, P.M.

Virus-like Particles in Vaccine Development. FUTURE MEDICINE LTD, 2014. p. 120-134.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Production of complex virus-like particles in insect cells

AU - Fernandes, Fabiana

AU - Teixeira, Ana P.

AU - Carinhas, Nuno

AU - Carrondo, Manuel J.T.

AU - Alves, P.M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A cost-effective manufacturing process yielding sufficient quantity and quality of a multigenic product is generally not an easy task to accomplish due to product complexity. Despite the success of the BEVS in producing VLP-based vaccines for both veterinary and human use, its performance regarding the expression of complex VLPs has room for improvement. The yields of correctly assembled VLPs and associated levels of baculovirus contamination are still not satisfactory according to commercial requirements. Significant efforts to address these issues continue to be directed towards ameliorating molecular design for the construction of more efficient and reliable expression systems. Nonreplicative rBVs represent one advance that aims at debottlenecking the problem of contamination of the VLP bulk with viral material. Stable protein expression through engineered insect cell lines constitutes another alternative since it does not rely on viral infection for protein production, thus minimizing downstream challenges. Still, VLP production will benefit from improvements in downstream processes that could improve recovery yields without compromising quality. Further work should also be conducted towards tuning the expression levels of each protein subunit to improve the assembly efficiency of complex VLPs and also the consistency of the final product composition. Ultimately, advances in the fields of systems biology and genetic engineering will complement each other towards the development of faster, robust and simpler production processes based on effective biological hosts and vectors. In the end, all will contribute to the sustainability of the insect cell technology and reinforce its credibility as a platform for the production of complex VLP vaccines.

AB - A cost-effective manufacturing process yielding sufficient quantity and quality of a multigenic product is generally not an easy task to accomplish due to product complexity. Despite the success of the BEVS in producing VLP-based vaccines for both veterinary and human use, its performance regarding the expression of complex VLPs has room for improvement. The yields of correctly assembled VLPs and associated levels of baculovirus contamination are still not satisfactory according to commercial requirements. Significant efforts to address these issues continue to be directed towards ameliorating molecular design for the construction of more efficient and reliable expression systems. Nonreplicative rBVs represent one advance that aims at debottlenecking the problem of contamination of the VLP bulk with viral material. Stable protein expression through engineered insect cell lines constitutes another alternative since it does not rely on viral infection for protein production, thus minimizing downstream challenges. Still, VLP production will benefit from improvements in downstream processes that could improve recovery yields without compromising quality. Further work should also be conducted towards tuning the expression levels of each protein subunit to improve the assembly efficiency of complex VLPs and also the consistency of the final product composition. Ultimately, advances in the fields of systems biology and genetic engineering will complement each other towards the development of faster, robust and simpler production processes based on effective biological hosts and vectors. In the end, all will contribute to the sustainability of the insect cell technology and reinforce its credibility as a platform for the production of complex VLP vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84956792376&partnerID=8YFLogxK

U2 - 10.2217/FMEB2013.13.67

DO - 10.2217/FMEB2013.13.67

M3 - Chapter

SN - 9781780844190

SP - 120

EP - 134

BT - Virus-like Particles in Vaccine Development

PB - FUTURE MEDICINE LTD

ER -

Fernandes F, Teixeira AP, Carinhas N, Carrondo MJT, Alves PM. Production of complex virus-like particles in insect cells. In Virus-like Particles in Vaccine Development. FUTURE MEDICINE LTD. 2014. p. 120-134 https://doi.org/10.2217/FMEB2013.13.67